The American Society of Hematology identified five hematologic tests and treatments that should be questioned to avoid adverse events and financial costs with low likelihood of benefit.
The ASH Choosing Wisely recommendations highlight five hematologic practices that should be questioned to avoid unnecessary risks and costs.
Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curative-intent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.
Hicks et al. (Wed,) conducted a review in Hematologic tests and treatments. ASH Choosing Wisely recommendations was evaluated. The American Society of Hematology identified five hematologic tests and treatments that should be questioned to avoid adverse events and financial costs with low likelihood of benefit.